Characterizing local and systemic exposure to clobetasol propionate in healthy subjects and patients with atopic dermatitis
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70102 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Janna K Duong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Modelling & Simulation, GSK, Australia. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Clobetasol, Models, Biological. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlasxoSmithKline.
Abstract (Originalsprache)
Aims
There is a potential risk of systemic side‐effects with the use of potent corticosteroids, such as clobetasol propionate (CP). This concern is of particular interest in paediatric patients. The aim of this study was to develop and verify a physiologically based pharmacokinetic (PBPK) model to describe the local and systemic exposure to CP following topical application over a period of up to 4 weeks.
Methods
Data from 12 clinical studies in healthy adult subjects and patients with atopic dermatitis (AD) were available for this investigation. A PBPK model including skin barrier impairment was developed to predict the effect of AD lesions on systemic exposure. Simulation scenarios were then evaluated to assess the effect of formulation, skin condition and surface area (5%–60% of body surface area [BSA]) on systemic exposure.
Results
The PBPK model described the absorption and disposition characteristics of CP. Mean clearance, volume of distribution (V ss ) and renal clearance were 27 L/h, 2.34 L/kg and 0.12 L/h, respectively. The half‐life of CP after topical application was significantly longer than after an IV dose (20.8 vs . 5.2 h). Systemic CP concentrations were higher with increasing surface area and skin barrier impairment. However, CP accumulates in the stratum corneum as the skin barrier function improves during treatment.
Conclusions
Systemic and local exposure to CP increases with impaired skin barrier in AD and larger application area. Given the recommended maximum dose of 50 g per week, CP should not be applied to an area of more than 30% of the BSA. Availability of this model will allow extrapolation of CP pharmacokinetics from adults to children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Modelling & Simulation, GSK, Australia.
- Clinical Pharmacology Modelling & Simulation, GSK, UK.
- Pharma Research and Development, Global Medical, GSK, Singapore.
- Pharmacological Research Foundation 'Gianni Benzi', Italy.
- Past professor of Pediatric Dermatology "Aldo Moro" University Bari, Italy.
- Clinical Pharmacology & Therapeutics Group, University College London, London, UK.
ORCID-Profile: Oscar Della Pasqua
Förderung
- GlasxoSmithKline
Zitieren
APA
Duong, J. K., van Dijkman, S., Ong, G., Marta, A., Ceci, A., Bonifazi, E., & Della Pasqua, O. (2025). Characterizing local and systemic exposure to clobetasol propionate in healthy subjects and patients with atopic dermatitis. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70102
Vancouver
Duong JK, van Dijkman S, Ong G, Marta A, Ceci A, Bonifazi E, et al. Characterizing local and systemic exposure to clobetasol propionate in healthy subjects and patients with atopic dermatitis. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70102
BibTeX
@article{Duong2025,
author = {Duong, Janna K and van Dijkman, Sven and Ong, Gary and Marta, Alexandra and Ceci, Adriana and Bonifazi, Ernesto and Della Pasqua, Oscar},
title = {Characterizing local and systemic exposure to clobetasol propionate in healthy subjects and patients with atopic dermatitis},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70102}
}
EUVIMED